Personalized Dietary Intervention in Managing Bowel Dysfunction and Improving Quality of Life in Stage I-III Rectosigmoid Cancer Survivors

Overview

This pilot clinical trial studies how well personalized dietary intervention works in managing bowel dysfunction and improving quality of life in stage I-III rectosigmoid cancer survivors. Personalized dietary intervention may help people understand bowel symptoms, identify helpful and troublesome foods for bowel symptoms, adjust diets and food preparation based on food triggers, and coach on healthy diet recommendations after cancer treatment.

Full Title of Study: “Pilot Study of a Personalized Dietary Intervention to Manage Bowel Dysfunction in Rectal Cancer Survivors”

Study Type

  • Study Type: Interventional
  • Study Design
    • Allocation: N/A
    • Intervention Model: Single Group Assignment
    • Primary Purpose: Supportive Care
    • Masking: None (Open Label)
  • Study Primary Completion Date: September 7, 2021

Detailed Description

PRIMARY OBJECTIVES: I. Administer and determine the feasibility of the personalized dietary intervention. II. Using qualitative methods, evaluate the acceptability of the intervention as reported by survivors. III. Explore decisional conflict associated with treatment decision-making in rectal cancer surgery. OUTLINE: At 6 months after standard of care treatment, patients receive 10 sessions of personalized dietary intervention over 30 minutes each over 4 months via the telephone. Patients also receive a workbook including reference materials and intervention content. After completion of study, patients are followed up for 6 months.

Interventions

  • Other: Informational Intervention
    • Receive a workbook
  • Other: Quality-of-Life Assessment
    • Ancillary studies
  • Other: Questionnaire Administration
    • Ancillary studies
  • Other: Survey Administration
    • Ancillary studies
  • Behavioral: Telephone-Based Intervention
    • Receive personalized dietary intervention

Arms, Groups and Cohorts

  • Experimental: Supportive Care (personalized dietary intervention)
    • At 6 months after standard of care treatment, patients receive 10 sessions of personalized dietary intervention over 30 minutes each over 4 months via the telephone. Patients also receive a workbook including reference materials and intervention content.

Clinical Trial Outcome Measures

Primary Measures

  • Acceptability assessed by semi-structured interview
    • Time Frame: Up to 6 months
    • Will be assessed through qualitative data analysis using conventional content analysis approach.
  • Bowel function assessed by Memorial Sloan Kettering Cancer Center Bowel Function Tool
    • Time Frame: Up to 6 months
    • Descriptive statistics will be summarized using validated scoring procedures.
  • Feasibility assessed by patient enrollment
    • Time Frame: Up to 6 months
    • Will be assessed through: 1) the ratio of eligible participants to those enrolled and those who declines participation; 2) reasons for non-participation; 3) number of scheduled study encounters completed; 4) attrition rate between pre- and post-intervention; 5) reasons for attrition/dropout; 6) level of intervention participation including the total number of sessions, number of sessions completed without break-offs, number of break-offs, length (minutes) of sessions; and 7) the ratio of all participants to those who complete >= 80% of the study.
  • Quality of life assessed by City of Hope-Quality of Life-Colorectal Cancer
    • Time Frame: Up to 6 months
    • Descriptive statistics will be summarized using validated scoring procedures.

Participating in This Clinical Trial

Inclusion Criteria

  • Diagnosis of stage I-III cancers of the rectosigmoid colon or rectum – 6 months post-treatment completion – Have a permanent ostomy or anastomosis – English-speaking – All subjects must have the ability to understand and the willingness to sign a written informed consent Exclusion Criteria:

  • Patients with stage IV disease will be excluded from the study – Subjects, who in the opinion of the investigator, may not be able to comply with the safety monitoring requirements of the study

Gender Eligibility: All

Minimum Age: 21 Years

Maximum Age: N/A

Are Healthy Volunteers Accepted: No

Investigator Details

  • Lead Sponsor
    • City of Hope Medical Center
  • Collaborator
    • National Cancer Institute (NCI)
  • Provider of Information About this Clinical Study
    • Sponsor
  • Overall Official(s)
    • Virginia Sun, PhD, RN, Principal Investigator, City of Hope Medical Center

Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.

At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.